Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points

References

• Diabetes Atlas 2014 Update. Brussels: International Diabetes Federation, 2014
   Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-88
   PubMed Web of Science ®Google Scholar
• Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014;16:492-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes. Expet Rev Endocrinol Metabol 2014;9:659-70
   PubMedGoogle Scholar
• Yabe D, Seino Y, Fukushima K, Seino S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diabetes Rep in press (DOI: 10.1007/s11892-015-0602-9)
   Google Scholar
• Yabe D, Kuwata H, Iwasaki M, Seino Y. Why are incretin-based therapies more efficient in East Asians? Perspectives from the pathophysiology of type 2 diabetes and East Asian dietary habits. Eur Med J in press
   Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 2014;16:900-9
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-23
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Progr Biophys Mol Biol 2011;107:248-56
   PubMed Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-88
   PubMed Web of Science ®Google Scholar
• Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014;124:2456-63
   PubMed Web of Science ®Google Scholar
• Ross SA. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr Med Res Opin 2015;31:125-35
   PubMed Web of Science ®Google Scholar
• Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta cell function. J Diabet Invest 2013;4:585-94
   PubMed Web of Science ®Google Scholar
• Meier JJ, Vilsbøll T, Donsmark M, et al. Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass. Diabetologia 2011;54:S1-S566 (Abstract 896)
   PubMed Web of Science ®Google Scholar
• Kondo Y, Satoh S, Nagakura J, et al. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 2013;4:571-5
   PubMed Web of Science ®Google Scholar
• King AB, Montanya E, Pratley RE, et al. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. Endocr Pract 2013;19:64-72
   PubMed Web of Science ®Google Scholar
• Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013;19:237-46
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42
   PubMed Web of Science ®Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82
   PubMed Web of Science ®Google Scholar
• Davies MJ, Kela R, Khunti K. Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-20
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Bohmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011;34:604-6
   PubMed Web of Science ®Google Scholar
• Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009;11:1153-62
   PubMed Web of Science ®Google Scholar
• Raccah D, Gourdy P, Sagnard L, Ceriello A. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes Metab Res Rev 2014;30:742-8
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Berria R, Lin J, et al. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. Adv Ther 2014;31:861-72
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014;28:880-6
   PubMed Web of Science ®Google Scholar
• Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab 2014;16:527-36
   PubMed Web of Science ®Google Scholar
• Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol 2012;11:142-9
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Li Y, Porter TK, et al. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c <7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab 2013;15:264-71
   PubMed Web of Science ®Google Scholar
• Grimm M, Li Y, Brunell SC, Blase E. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med 2013;125:101-8
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2:289-97
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384:1349-57
   PubMed Web of Science ®Google Scholar
• Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15:485-502
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228-34
   PubMed Web of Science ®Google Scholar
• Yabe D, Ambos A, Cariou B, et al. Adjunctive lixisenatide treatment improves glycemic control in patients with T2DM irrespective of b-cell function. Diabetes 2014;64(Suppl 1):A253
   Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 2014;370:794-7
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17
   PubMed Web of Science ®Google Scholar
• Waser B, Blank A, Karamitopoulou E, et al. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 2014;28:391-402
   PubMed Web of Science ®Google Scholar
• Koehler JA, Baggio LL, Yusta B, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 2015;21:379-91
   PubMed Web of Science ®Google Scholar
• McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 2014;86:241-58
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730-6
   PubMed Web of Science ®Google Scholar